BAUDETTE, Minn., July 6, 2020 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the
acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and
200mg from a private company for $3.0
million. The current annual U.S. market for this
product is approximately $40 million,
according to IQVIA/IMS Health.
Patrick Walsh, ANI's Interim
President and CEO stated, "We are excited to add Fluconazole
Tablets, currently manufactured at our site in Oakville,
Canada, to our commercial generic
portfolio. With this acquisition we further advance our
strategy of expanding the ANI product portfolio via the Oakville
plant. By leveraging our commercial, manufacturing and
packaging capabilities we expect to enhance the margin opportunity
and competitive position of this product."
About Fluconazole Tablets USP
Fluconazole Tablets USP is indicated for the treatment of
vaginal candidiasis (vaginal yeast infections due to Candida)
and oropharyngeal and esophageal candidiasis. In open
noncomparative studies of relatively small numbers of patients,
fluconazole was also effective for the treatment
of Candida urinary tract infections, peritonitis, and
systemic Candida infections including candidemia,
disseminated candidiasis, and pneumonia. It is also indicated to
decrease the incidence of candidiasis in patients undergoing bone
marrow transplantation who receive cytotoxic chemotherapy and/or
radiation therapy.
For more information, including the complete list of indications
and usages, please see the Full Prescribing Information.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, those relating to the manufacturing and commercialization of
the acquired product and any additional products manufactured at
the Oakville, Canada site and
other statements that are not historical in nature, particularly
those that utilize terminology such as "anticipates," "will,"
"expects," "plans," "potential," "future," "believes," "intends,"
"continue," other words of similar meaning, derivations of such
words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; competition from other
products; acquisitions; contract manufacturing arrangements; delays
or failure in obtaining product approval from the U.S. Food and
Drug Administration; general business and economic conditions;
market trends; products development; regulatory and other approvals
and marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission
("SEC"), including its most recent annual report on Form 10-K and
quarterly reports on Form 10-Q, as well as other filings with the
SEC. All forward-looking statements in this news release speak only
as of the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticalscom
View original
content:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-acquisition-of-fluconazole-tablets-301088173.html
SOURCE ANI Pharmaceuticals, Inc.